Randomized Trial of Long-Term Oral Acyclovir Usage to Prevent Varicella Zoster Virus Infection After Allogeneic Bone Marrow Transplant
Herpes zoster infection occurs in 30% of allogeneic hematopoietic cell transplant (HCT)
recipients who had a history of varicella zoster virus (VZV) infection. A safe and
effective prevention strategy has not been established.
77 marrow allograft recipients at risk for VZV reactivation were randomized to oral
acyclovir 800 mg twice daily or placebo given from day 30 until day 365 and were followed
for toxicity and clinical evidence of herpes zoster infection.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind
VZV infection at one year
Michael Boeckh, MD
Fred Hutchinson Cancer Research Center
United States: Food and Drug Administration
FHCRC IR 420
|Fred Hutchinson Cancer Research Center||Seattle, Washington 98109|